grant
Imaging and Genomic Signatures of Brain Tumor Heterogeneity and Evolution to Optimize Patient Management
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Jul 2007Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY20252-ketoglutarate2-oxoglutarate21+ years old3-D Imaging3D imagingAccelerationAchievementAchievement AttainmentAddressAdultAdult HumanAlanineAutomobile DrivingBiologicalBiological MarkersBrain NeoplasiaBrain NeoplasmsBrain TumorsCategoriesCell LineCellLineCharacteristicsClassificationClinicalClinical ServicesDNA MethylationDNA mutationDevelopmentDiseaseDisorderEarly treatmentEvaluationEvolutionFKHL16FOXM1FOXM1 geneFOXM1BForkhead Box M1Forkhead Box M1B Transcription FactorForkhead, Drosophila, Homolog-Like 16FosteringGene ExpressionGenetic ChangeGenetic defectGenetic mutationGenomicsGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGlutamatesGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrantGroupingHFH11HeterogeneityHumanImageImaging ProceduresImaging TechnicsImaging TechniquesInfrastructureIntracranial Central Nervous System NeoplasmsIntracranial Central Nervous System TumorsIntracranial NeoplasmsIntracranial TumorIntratumoral heterogeneityInvestigatorsKnowledgeL-GlutamateLabelLeadershipLesionMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMerlinMetabolicModelingModern ManMoesin-Ezrin-Radixin-Like ProteinMolecularMonitorMutateMutationNF2NF2 Gene ProductNF2 geneNMR ImagingNMR TomographyNeurofibromatosis 2 Gene ProductNeurofibromatosis 2 GenesNeurofibromatosis Type 2 ProteinNeurofibromin 2Neuroglial NeoplasmNeuroglial TumorNewly DiagnosedNuclear Magnetic Resonance ImagingOperative ProceduresOperative Surgical ProceduresOrganoidsOutcomePatient CarePatient Care DeliveryPatient imagingPatientsPrimary Brain NeoplasmsPrimary Brain TumorsPropertyPyruvateRadiationRecurrenceRecurrentResearchResearch PersonnelResearch ResourcesResearchersResistanceResourcesRoleSamplingSchwannomerlinSchwannominSchwannomin ProteinStrains Cell LinesSurgicalSurgical InterventionsSurgical ProcedureSystemSystematicsTRIDENT geneTRIDENT proteinTechniquesTechnologyTherapeuticThree-Dimensional ImagingTimeTissue SampleTranslatingTranslationsTumor PathologyWorkZeugmatographyadulthoodalpha ketoglutaratebio-markersbiologicbiologic markerbiomarkercancer cell metabolismcancer imagingcancer metabolismcare for patientscare of patientscaring for patientsclinical applicabilityclinical applicationclinical translationclinical validationclinically translatablecultured cell linedevelopmentaldrivingearly therapyexperienceexpression subtypesgenome mutationgenomic datagenomic datasetgenomic signatureglial-derived tumorglioblastoma multiformeglutamatergicgroupingsheterogeneity in tumorsimage-based methodimagingimaging biomarkerimaging in patientsimaging markerimaging methodimaging modalityimaging on patientsimaging probeimaging scientistimaging-based biological markerimaging-based biomarkerimaging-based markerimprovedindividual patientinnovateinnovationinnovativeinsightintra-tumoral heterogeneityintratumor heterogeneitymeningiomametabolic imagingmolecular imagingmolecular sub-typesmolecular subsetsmolecular subtypesmolecule imagingmultidisciplinarymultiparametric imagingneuroglia neoplasmneuroglia tumornew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeutic targetnew therapeuticsnew therapynew therapy approachesnew therapy targetnew treatment approachnew treatment strategynext generation therapeuticsnf 2 Genesnon-invasive imagingnoninvasive imagingnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy approachnovel therapy targetoncologic imagingoncology imagingpre-clinicalpre-clinical evaluationpreclinicalpreclinical evaluationprognosticpromoterpromotorresistantresponseresponse to therapyresponse to treatmentsocial rolespatial and temporalspatial temporalspatiotemporalspongioblastoma multiformestandard carestandard treatmentsuccesssurgerytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapeutic targettherapy responsetranslationtranslational cancer researchtreatment responsetreatment responsivenesstumortumor cell metabolismtumor diagnosistumor heterogeneitytumor imagingtumor metabolismtumors in the brainα-ketoglutarateα-oxoglutarateαKG
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
OVERALL: PROJECT ABSTRACT
The overall goal of this renewal P01 proposal is to identify imaging and genomic signatures of brain tumor
heterogeneity and evolution to optimize patient management of the two most common primary brain tumors in
adults: glioblastoma and meningioma. The hallmark of glioblastoma is resistance to standard treatment with…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click